Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B
Top Cited Papers
- 23 June 2003
- journal article
- clinical trial
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 10 (4) , 298-305
- https://doi.org/10.1046/j.1365-2893.2003.00450.x
Abstract
Current therapies for chronic hepatitis B (CHB) have a number of limitations, and better treatment options are needed. Peginterferon α‐2a (40 kDa) is superior to conventional interferon α‐2a in the t...Keywords
This publication has 28 references indexed in Scilit:
- Efficacy and Safety of Pegylated (40–Kd) Interferon α–2A Compared With Interferon α–2A in Noncirrhotic Patients With Chronic Hepatitis CHepatology, 2001
- Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutantsHepatology, 2000
- Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trialGut, 2000
- Quantitation of Hepatitis B Viremia and Emergence of YMDD Variants in Patients with Chronic Hepatitis B Treated with LamivudineThe Journal of Infectious Diseases, 1999
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesNew England Journal of Medicine, 1999
- Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis BHepatology, 1999
- Immunomodulation and Therapeutic Effects of the Oral Use of Interferon-alpha: Mechanism of ActionJournal of Interferon & Cytokine Research, 1999
- Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapyHepatology, 1999
- Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosisHepatology, 1998
- Comparative study of three doses of interferon-α2a in chronic active hepatitis BJournal of Viral Hepatitis, 1994